产品
编 号：F153373
分子式：C26H45NO21
分子量：707.63
分子式：C26H45NO21
分子量：707.63
产品类型
规格
价格
是否有货
结构图
CAS No: 14116-68-8
产品详情
生物活性：
Lacto-N-tetraose is the significant core structure of human milk oligosaccharides (HMOs) naturally existing in human milk. Lacto-N-tetraose is consist of galactose, N-acetylglucosamine, and glucose moieties. Lacto-N-tetraose has prebiotic effect, immune regulatory effect, anti-inflammatory effects, intestinal cell responses regulatory effect, antibacterial activity and antiviral activity. Lacto-N-tetraose has been widely added to infant formula.
体内研究：
Lacto-N-tetraose (1000-4000?mg/kg; p.o.; daily for 90 days) does not show toxicity in neonatal SD rats.Animal Model:Female neonatal SD rats (housed together with dam until weaning after 21 days)
Dosage:1000, 25000 and 4000?mg/kg?
Administration:p.o.; daily for 90 days
Result:Did not show toxicity on clinical observations, body weight, food consumption, development and maturation, clinical pathology, organ weights or histopathology.
体外研究：
HMOs exhibits antimicrobial and antibiofilm activity against Streptococcus agalactiae, antibiofilm activity against Methicillin-resistant Staphylococcus aureus (MRSA), and antimicrobial activity against both Acinetobacter baumannii and Clostridium difficile.Lacto-N-tetraose (500-2000 μg/mL) does not cause clastogenic or aneugenic signs in human peripheral blood lymphocytes, nor increase the percentage of micronucleated cells.
Lacto-N-tetraose is the significant core structure of human milk oligosaccharides (HMOs) naturally existing in human milk. Lacto-N-tetraose is consist of galactose, N-acetylglucosamine, and glucose moieties. Lacto-N-tetraose has prebiotic effect, immune regulatory effect, anti-inflammatory effects, intestinal cell responses regulatory effect, antibacterial activity and antiviral activity. Lacto-N-tetraose has been widely added to infant formula.
体内研究：
Lacto-N-tetraose (1000-4000?mg/kg; p.o.; daily for 90 days) does not show toxicity in neonatal SD rats.Animal Model:Female neonatal SD rats (housed together with dam until weaning after 21 days)
Dosage:1000, 25000 and 4000?mg/kg?
Administration:p.o.; daily for 90 days
Result:Did not show toxicity on clinical observations, body weight, food consumption, development and maturation, clinical pathology, organ weights or histopathology.
体外研究：
HMOs exhibits antimicrobial and antibiofilm activity against Streptococcus agalactiae, antibiofilm activity against Methicillin-resistant Staphylococcus aureus (MRSA), and antimicrobial activity against both Acinetobacter baumannii and Clostridium difficile.Lacto-N-tetraose (500-2000 μg/mL) does not cause clastogenic or aneugenic signs in human peripheral blood lymphocytes, nor increase the percentage of micronucleated cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备